Compare · COO vs STAA
COO vs STAA
Side-by-side comparison of The Cooper Companies Inc. (COO) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COO and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 17.1x STAA ($1.12B).
- COO has been more active in the news (6 items in the past 4 weeks vs 4 for STAA).
- Both have 25 recent analyst ratings on file.
- Company
- The Cooper Companies Inc.
- STAAR Surgical Company
- Price
- -
- -
- Market cap
- $19.03B
- $1.12B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 25
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest COO
- Barclays initiated coverage on Cooper with a new price target
- New CooperVision® Consumer Insights Report Reveals Multifocal Contact Lenses Are Viewed as a Leading Anti-Aging Solution
- Seneca Polytechnic and CooperVision Canada open Contact Lens Centre of Excellence to help advance the future of vision care
- COOPER COMPANIES, INC. COO INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 14.7% Share Drop
- CooperCompanies Unveils Accelerated CooperVision Innovation Strategy at The Vision Centre Opening
- CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements
- JANA Partners Sends Letter to Cooper Board of Directors
- Director Kurzius Lawrence Erik bought $549,320 worth of shares (10,000 units at $54.93), increasing direct ownership by 47% to 31,099 units (SEC Form 4)
- Director Rosebrough Walter M Jr bought $541,640 worth of shares (10,000 units at $54.16) (SEC Form 4)
- Director Kurzius Lawrence Erik bought $539,150 worth of shares (10,000 units at $53.91), increasing direct ownership by 90% to 21,099 units (SEC Form 4)
Latest STAA
- STAAR Surgical Names Andrew Pilon as Vice President of Business Development
- Amendment: STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical upgraded by Stifel with a new price target
- STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
- STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
- STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company